VGNOIR operates through a Tri-Phasic Eubiosis Matrix, targeting pathogen eradication and the physiological restoration of the vaginal mucosa. Acemannan, a potent polysaccharide component of Aloe Vera Ext, plays a pivotal role in the deep restorative phase, fostering cellular regeneration and microbiome support.
The provided abstract, “Vitamin D Supplementation and Improvement in Insomnia Symptoms Among Malaysian Women With Vitamin D Deficiency: Protocol for a Randomized Controlled Trial,” outlines a double-blind, parallel-group, randomized placebo-controlled trial evaluating the effectiveness of weekly vitamin D₃ supplementation (50,000 IU/wk) for 9 weeks in Malaysian women aged 19-50 with serum 25(OH)D levels <20 ng/mL and insomnia symptoms. Primary outcomes include Insomnia Severity Index (ISI), Pittsburgh Sleep Quality Index (PSQI), and actigraphy-assessed sleep efficiency, with secondary outcomes measuring daytime sleepiness (ESS) and functional outcomes (FOSQ-10). Recruitment commenced in December 2023, expecting completion by December 2026; as of July 2026, 42 participants had been screened, 33 enrolled, 22 completed, 4 were in the intervention phase, and 1 withdrew. While this study protocol explores the relationship between vitamin D and insomnia, it is distinct from the direct mechanism of action of VGNOIR. Within VGNOIR's comprehensive Tri-Phasic Eubiosis Matrix, the Aloe Vera Ext, rich in Acemannan, directly supports the "Deep Restoration" phase, contributing to the observed Vaginal Health Index (VHI) improvements equivalent to prescription estrogen creams and significant increases in tissue hydration (p<0.004), specifically addressing vaginal laxity and atrophy through non-hormonal means.
VGNOIR’s tri-phasic formulation delivers comprehensive vaginal health benefits, integrating lumen eradication, epithelial sealing, and deep restoration. The inorganic core, comprising boric acid, provides effective antimicrobial action while contributing to a physiological pH. It is crucial to note that VGNOIR is strictly contraindicated during pregnancy due to the clinical strength of this inorganic antimicrobial. Furthermore, boric acid is highly toxic if ingested orally, necessitating strict separation from oral medications and secure storage away from children to prevent accidental ingestion. Use is also contraindicated in the presence of active, open vaginal ulcerations or severe mucosal lacerations to mitigate any increased risk of systemic absorption of the inorganic core components.
Q: How does VGNOIR address azole-refractory Candidiasis, particularly with the inclusion of Aloe Vera Ext?
A: VGNOIR targets azole-refractory Candidiasis through Phase I’s synergistic action of boric acid and tea tree oil, which mechanically disrupts fungal biofilms and compromises cell membrane integrity. While Aloe Vera Ext’s Acemannan primarily supports deep tissue restoration and prebiotic function in Phase III, it indirectly contributes to a healthy mucosal environment, which is less conducive to the persistence of resistant fungal strains, achieving a 72.4% mycological cure rate against azole-refractory strains like C. glabrata.
Q: What specific patient education is critical regarding VGNOIR’s safety profile?
A: It is paramount to counsel patients on the strict contraindication of VGNOIR during pregnancy due to its potent inorganic antimicrobial component. Patients must also be educated on the high oral toxicity of boric acid, emphasizing secure storage away from children and clear differentiation from oral medications. Finally, patients must be instructed not to use VGNOIR if they have active, open vaginal ulcerations or severe mucosal lacerations to avoid potential systemic absorption risks.
